ES2806873T3 - Piridinas sustituidas con heteroarilo y métodos de uso - Google Patents

Piridinas sustituidas con heteroarilo y métodos de uso Download PDF

Info

Publication number
ES2806873T3
ES2806873T3 ES17728272T ES17728272T ES2806873T3 ES 2806873 T3 ES2806873 T3 ES 2806873T3 ES 17728272 T ES17728272 T ES 17728272T ES 17728272 T ES17728272 T ES 17728272T ES 2806873 T3 ES2806873 T3 ES 2806873T3
Authority
ES
Spain
Prior art keywords
independently selected
sulfonyl
optionally substituted
trifluoromethoxy
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17728272T
Other languages
English (en)
Spanish (es)
Inventor
Robert J Altenbach
Andrew Bogdan
Ghjuvanni Petru Diunisu Coti
Marlon D Cowart
Stephen N Greszler
Hans Kelgtermans
Philip R Kym
Der Plas Steven Emiel Van
Xueqing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
AbbVie Overseas SARL
Original Assignee
Galapagos NV
AbbVie Overseas SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV, AbbVie Overseas SARL filed Critical Galapagos NV
Application granted granted Critical
Publication of ES2806873T3 publication Critical patent/ES2806873T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES17728272T 2016-06-03 2017-05-24 Piridinas sustituidas con heteroarilo y métodos de uso Active ES2806873T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345315P 2016-06-03 2016-06-03
PCT/IB2017/053068 WO2017208115A1 (en) 2016-06-03 2017-05-24 Heteroaryl substituted pyridines and methods of use

Publications (1)

Publication Number Publication Date
ES2806873T3 true ES2806873T3 (es) 2021-02-18

Family

ID=59014678

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17728272T Active ES2806873T3 (es) 2016-06-03 2017-05-24 Piridinas sustituidas con heteroarilo y métodos de uso

Country Status (35)

Country Link
US (2) US10138227B2 (Direct)
EP (1) EP3464282B1 (Direct)
JP (3) JP6968094B2 (Direct)
KR (2) KR102719916B1 (Direct)
CN (2) CN109311864B (Direct)
AR (2) AR108672A1 (Direct)
AU (3) AU2017273215B2 (Direct)
CA (1) CA3022216A1 (Direct)
CL (1) CL2018003323A1 (Direct)
CO (1) CO2018012171A2 (Direct)
CR (1) CR20180547A (Direct)
CY (1) CY1124031T1 (Direct)
DK (1) DK3464282T3 (Direct)
DO (1) DOP2018000257A (Direct)
EC (1) ECSP18094790A (Direct)
ES (1) ES2806873T3 (Direct)
HR (1) HRP20201068T1 (Direct)
HU (1) HUE050248T2 (Direct)
IL (3) IL303196B2 (Direct)
LT (1) LT3464282T (Direct)
MX (2) MX385054B (Direct)
MY (1) MY199604A (Direct)
PE (1) PE20190511A1 (Direct)
PH (1) PH12018502534B1 (Direct)
PL (1) PL3464282T3 (Direct)
PT (1) PT3464282T (Direct)
RS (1) RS60574B1 (Direct)
RU (2) RU2021127810A (Direct)
SG (1) SG11201808842VA (Direct)
SI (1) SI3464282T1 (Direct)
SM (1) SMT202000394T1 (Direct)
TW (4) TWI797926B (Direct)
UY (2) UY40612A (Direct)
WO (1) WO2017208115A1 (Direct)
ZA (1) ZA201808423B (Direct)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100921397B1 (ko) * 2009-02-09 2009-10-14 (주)오엠티 인쇄회로기판의 세척장비 및 이를 이용한 세척방법
SG10201913603QA (en) 2014-10-06 2020-02-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US10570115B2 (en) 2016-09-30 2020-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
HRP20201946T1 (hr) 2016-12-09 2021-01-22 Vertex Pharmaceuticals Incorporated Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutski sastavi, postupci liječenja, i postupak za dobivanje modulatora
US20200123137A1 (en) 2016-12-20 2020-04-23 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
MA51039A (fr) 2017-12-08 2020-10-14 Vertex Pharma Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
MD3752510T2 (ro) 2018-02-15 2023-06-30 Vertex Pharma Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
IT201900000687A1 (it) 2019-01-16 2020-07-16 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
AR118555A1 (es) 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2021011327A1 (en) 2019-07-12 2021-01-21 Orphomed, Inc. Compound for treating cystic fibrosis
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
CA3150162A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CA3158057A1 (en) * 2019-11-12 2021-05-20 Genzyme Corporation 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity
JP2023538125A (ja) 2020-08-20 2023-09-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 粘液過剰分泌を特徴とする呼吸器疾患を処置するための方法
KR20230118123A (ko) 2020-12-10 2023-08-10 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법
WO2022150174A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
MX2024002008A (es) 2021-08-19 2024-03-05 Syngenta Crop Protection Ag Metodo para controlar plagas resistentes a diamidas y compuestos para el mismo.
CA3267788A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd COMBINATION OF MACROCYCLIC CFTR MODULATORS WITH CFTR CORRECTORS AND/OR CFTR POTENTIALIZERS
CN119894906A (zh) 2022-09-15 2025-04-25 爱杜西亚药品有限公司 大环cftr调节剂
CN116813569B (zh) * 2023-07-10 2024-07-02 衡阳市中心医院 一种抗癌药中间体的制备方法和抗癌药的制备方法
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561560A1 (en) * 2004-03-30 2005-10-13 The Regents Of The University Of California Hydrazide-containing cftr inhibitor compounds and uses thereof
CA2569402A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
PL2502911T3 (pl) 2004-06-24 2017-09-29 Vertex Pharma Modulatory transporterów kasety wiążącej ATP
CN101668732A (zh) * 2007-04-02 2010-03-10 同一世界健康研究院 Cftr抑制剂化合物及其用途
CA2688004C (en) 2007-05-25 2016-07-05 Vertex Pharmaceuticals Incorporated Thienopyridone compounds for use as modulators of cystic fibrosis transmembrane conductance regulator
AR069637A1 (es) 2007-12-10 2010-02-10 Novartis Ag Derivados de pirazinas
JP5637859B2 (ja) 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
DK2349263T3 (da) * 2008-10-23 2014-07-21 Vertex Pharma Modulatorer af transmembranledningsevneregulatoren for cystisk fibrose
US8436014B2 (en) 2008-10-23 2013-05-07 Vertex Pharmaceutical Incorporated Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide
JP5699090B2 (ja) 2008-12-30 2015-04-08 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
WO2011008931A2 (en) * 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
KR101886459B1 (ko) 2010-10-08 2018-08-07 니발리스 테라퓨틱스, 인코포레이티드 S-나이트로소글루타티온 리덕타제 억제제로서의 신규한 치환된 퀴놀린 화합물
WO2012154880A1 (en) * 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
ES2558457T3 (es) * 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
HUE041740T2 (hu) 2011-09-20 2019-05-28 Univ North Carolina Chapel Hill Nátriumcsatornák szabályozása PLUNC-fehérjékkel
CN105531268B (zh) 2013-05-07 2017-09-12 加拉佩格斯股份有限公司 用于治疗囊性纤维化的新化合物及其药物组合物
US9133210B2 (en) 2013-08-08 2015-09-15 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
US9745292B2 (en) 2014-03-13 2017-08-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
EP3116501A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
JP6615213B2 (ja) 2014-10-31 2019-12-04 アッヴィ・エス・ア・エール・エル 置換テトラヒドロピランおよび使用方法
RU2718060C2 (ru) 2014-10-31 2020-03-30 Эббви С.А.Р.Л. Замещенные хроманы
HK1249893A1 (zh) * 2015-03-31 2018-11-16 Vertex Pharmaceuticals (Europe) Limited 氘代vx-661
RU2017146661A (ru) * 2015-06-02 2019-07-15 Эббви С.А.Р.Л. Замещенные пиридины и способ их применения
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
CN108431002A (zh) 2015-10-09 2018-08-21 艾伯维公司 取代的吡唑并[3，4-b]吡啶-6-甲酸及其用途
SI3359541T1 (sl) 2015-10-09 2021-01-29 Abbvie Overseas S.A R.L. N-sulfonirani pirazolo(3,4 b)piridin-6-karboksamidi in postopki uporabe
EP3448842A1 (en) 2016-04-26 2019-03-06 AbbVie S.À.R.L. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use

Also Published As

Publication number Publication date
KR102469995B1 (ko) 2022-11-24
CY1124031T1 (el) 2022-03-24
KR20190015215A (ko) 2019-02-13
LT3464282T (lt) 2020-09-10
IL303196A (en) 2023-07-01
IL262415A (en) 2018-12-31
TW202214614A (zh) 2022-04-16
SI3464282T1 (sl) 2020-12-31
PL3464282T3 (pl) 2020-12-14
IL303196B1 (en) 2024-12-01
TWI797926B (zh) 2023-04-01
HRP20201068T1 (hr) 2020-11-13
ZA201808423B (en) 2019-08-28
JP6968094B2 (ja) 2021-11-17
EP3464282B1 (en) 2020-04-22
RU2018138707A3 (Direct) 2020-08-24
TWI752961B (zh) 2022-01-21
MX2018014758A (es) 2019-04-29
RS60574B1 (sr) 2020-08-31
CN114671864A (zh) 2022-06-28
AR108672A1 (es) 2018-09-12
TW202329959A (zh) 2023-08-01
JP7392211B2 (ja) 2023-12-06
AR124916A2 (es) 2023-05-17
TWI849782B (zh) 2024-07-21
UY40612A (es) 2024-02-15
US10604515B2 (en) 2020-03-31
KR20220162806A (ko) 2022-12-08
PH12018502534A1 (en) 2019-10-21
BR112018074815A2 (pt) 2019-03-19
AU2024202468A1 (en) 2024-05-02
US10138227B2 (en) 2018-11-27
AU2021282409A1 (en) 2021-12-23
NZ788542A (en) 2025-06-27
CN109311864A (zh) 2019-02-05
SG11201808842VA (en) 2018-11-29
NZ747222A (en) 2025-06-27
JP7622122B2 (ja) 2025-01-27
IL288243B1 (en) 2023-07-01
PE20190511A1 (es) 2019-04-10
JP2019517455A (ja) 2019-06-24
US20170349576A1 (en) 2017-12-07
CA3022216A1 (en) 2017-12-07
CN114671864B (zh) 2025-04-08
DOP2018000257A (es) 2018-12-31
MY199604A (en) 2023-11-08
CL2018003323A1 (es) 2019-03-22
PH12018502534B1 (en) 2020-09-23
PT3464282T (pt) 2020-07-17
IL288243B2 (en) 2023-11-01
WO2017208115A1 (en) 2017-12-07
JP2023172889A (ja) 2023-12-06
IL288243A (en) 2022-01-01
KR102719916B1 (ko) 2024-10-23
JP2022009448A (ja) 2022-01-14
RU2018138707A (ru) 2020-07-14
MX385054B (es) 2025-03-14
IL262415B (en) 2021-12-01
UY37272A (es) 2018-01-02
HUE050248T2 (hu) 2020-12-28
CO2018012171A2 (es) 2018-11-30
CN109311864B (zh) 2022-05-10
AU2017273215A1 (en) 2018-10-25
TW201802085A (zh) 2018-01-16
MX2021009322A (es) 2021-09-08
RU2756743C2 (ru) 2021-10-05
RU2021127810A (ru) 2021-10-25
IL303196B2 (en) 2025-04-01
EP3464282A1 (en) 2019-04-10
ECSP18094790A (es) 2019-01-31
CR20180547A (es) 2019-10-30
DK3464282T3 (da) 2020-07-27
AU2021282409B2 (en) 2024-01-18
AU2017273215B2 (en) 2021-09-09
US20190055229A1 (en) 2019-02-21
SMT202000394T1 (it) 2020-09-10
TW202515560A (zh) 2025-04-16

Similar Documents

Publication Publication Date Title
ES2806873T3 (es) Piridinas sustituidas con heteroarilo y métodos de uso
ES2774066T3 (es) Tricíclicos sustituidos y métodos de uso
ES2829636T3 (es) Pirazolo[3,4-b]piridin-6-carboxamidas N-sulfoniladas y método de uso
ES2773046T3 (es) Cianopirrolidinas como inhibidores de DUB para el tratamiento del cáncer
US10047051B2 (en) Substituted pyridines and method of use
HK40006841B (en) Heteroaryl substituted pyridines and methods of use
HK40006841A (en) Heteroaryl substituted pyridines and methods of use
BR112018074815B1 (pt) Composto de piridina substituída com heteroarila
BR122024019066B1 (pt) Composto de piridina substituída com heteroarila, composições farmacêuticas que compreendem o mesmo e usos do mesmo para tratar fibrose cística
BR122024019066A2 (pt) Composto de piridina substituída com heteroarila, composições farmacêuticas que compreendem o mesmo e usos do mesmo para tratar fibrose cística